Tenderwize
Zurück zur Suche

Open-house biologics rebate agreement for Teriparatide

Techniker Krankenkasse·Hamburg, Germany·Deadline Apr 29, 2028 · 614 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-06 - Teriparatid

61/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

61 / 100

Komplexität

56 / 100

Risikofaktoren

The structured data gives a deadline of 2028-04-29 21:59:59 UTC, while the XML text also mentions 2028-04-30 as an end...

The notice says offers/contracts cannot be submitted via the portal; submission must be by email with qualified electro...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Conclusion of rebate agreements for the active substance Teriparatid.
  • Supply arrangement for pharmaceutical products under an open-house model.
Vollständige Zusammenfassung anzeigen

Open-house supply arrangement for pharmaceutical products (Teriparatid) led by Techniker Krankenkasse with HEK and hkk as participating buyers. The procedure is non-exclusive, with no individual negotiations and uniform conditions for all suitable pharmaceutical undertakings. The contract term is up to 24 months from 01.05.2026 and ends no later than 30.04.2028. Documents are available online, but only the XML/tender text was provided here, so procurement documents were not fully analyzed.

Risiken

The structured data gives a deadline of 2028-04-29 21:59:59 UTC, while the XML text also mentions 2028-04-30 as an end...

The notice says offers/contracts cannot be submitted via the portal; submission must be by email with qualified electro...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • The bidder must be a pharmaceutical undertaking within the meaning of § 4(18) AMG for the offered medicinal products.
  • The bidder must have its seat in the AMG territory, another EU Member State, or an EEA state.
  • A valid marketing authorization for the contract medicinal product(s) is required, or another legal basis to place the product on the market in its own name.

Zuschlagskriterien

Lot 1

No explicit award criteria provided; open-house uniform conditions only.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house biologics rebate agreement for Teriparatide

Supply contract for Teriparatid under an open-house procedure. Scope is nationwide in Germany. The arrangement is non-exclusive and open to all eligible pharmaceutical undertakings during the contract period.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Apr 2026 - Apr 2028

Kategorie

Pharmaceutical products

Zuschlagskriterien

No explicit award criteria provided; open-house uniform conditions only.

Frist

Deadline Apr 29, 2028

Vergabedetails

Veröffentlichungsdatum
15 Mar 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
179543-2026

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3